Molbio Diagnostics IPO: Price Band, Dates, Lot Size, GMP, Financials and IPO Details

The Molbio Diagnostics IPO is set to attract investor attention as the Goa-based molecular diagnostics company enters the public markets. The IPO opened for subscription on August 10, 2026, and will remain open until August 12, 2026.

Molbio Diagnostics is known for its point-of-care molecular diagnostic solutions, particularly the Truenat platform. The company has built a presence in India and international markets and is focused on making molecular diagnostics more accessible through portable and decentralized testing solutions.

The IPO comprises a combination of a fresh issue of ₹200 crore and an Offer for Sale (OFS) of shares held by existing shareholders. At the upper price band of ₹807 per share, the total issue size is approximately ₹939.70 crore.

Molbio Diagnostics IPO – Key Details

At the upper price band of ₹807, retail investors need a minimum investment of ₹14,526 for one lot of 18 shares.

What Does Molbio Diagnostics Do?

Molbio Diagnostics is a molecular diagnostics company focused on point-of-care testing. Its flagship Truenat platform is designed to enable molecular testing closer to the patient rather than relying entirely on centralized laboratories.

The company’s technology portfolio is aimed at infectious diseases and other diagnostic applications. Its products are used across government healthcare programmes, hospitals, diagnostic laboratories and international healthcare markets.

The company has manufacturing facilities in India and serves customers across numerous international markets. Recent reports indicate that Molbio’s products are available in more than 90 countries, highlighting the company’s international reach.

Truenat: The Company’s Key Technology

The Truenat platform is one of Molbio Diagnostics’ major differentiators.

It is a portable, battery-operated real-time PCR platform designed for decentralized molecular diagnostics. The platform can be deployed in settings where access to sophisticated centralized laboratories may be limited.

This model can be particularly relevant in emerging markets and remote areas, where rapid diagnosis can help improve access to healthcare.

Molbio has developed multiple assays for the Truenat platform, allowing the same underlying diagnostic infrastructure to be used for testing different diseases.

Molbio Diagnostics IPO Issue Structure

The IPO consists of two components:

Fresh Issue – ₹200 Crore

Molbio Diagnostics will raise ₹200 crore through the fresh issue of equity shares.

The company plans to use the fresh issue proceeds primarily for expansion and capital expenditure.

Offer for Sale – ₹739.70 Crore

The remaining approximately ₹739.70 crore will come through an Offer for Sale by existing shareholders.

In an OFS, the money raised from the sale of shares goes to the selling shareholders rather than to the company.

Therefore, investors should distinguish between the fresh issue, which provides capital to Molbio, and the OFS, which allows existing shareholders to partially monetise their holdings.

How Will Molbio Use IPO Proceeds?

According to the IPO details, a significant portion of the fresh issue proceeds will be directed toward expanding the company’s infrastructure.

Approximately ₹106 crore is proposed to be used for capital expenditure related to a new R&D facility, Centre of Excellence and connected office space.

Another approximately ₹72 crore is proposed for purchasing plant, machinery and other equipment for the company’s Goa Unit I, Goa Unit II and Visakhapatnam unit.

The balance is intended for general corporate purposes.

The proposed investment indicates that Molbio is looking to strengthen both its research capabilities and manufacturing infrastructure.

Molbio Diagnostics IPO Financial Performance

Financial performance will be one of the key factors investors should consider while evaluating the IPO.

Molbio has developed a business model around proprietary diagnostic technology, manufacturing and recurring demand for diagnostic assays.

The company’s growth opportunity is supported by increasing demand for rapid diagnostics, decentralized healthcare and molecular testing.

However, investors should review the detailed financial statements in the IPO prospectus, including revenue growth, profit margins, cash flows, debt levels and return ratios, before making an investment decision.

Global Presence

One of Molbio’s important strengths is its international footprint.

The company has expanded its diagnostic products beyond India and serves healthcare markets across Asia, Africa and other international regions.

The company’s decentralized testing model can be particularly useful in countries where centralized laboratory infrastructure is limited.

This international presence provides Molbio with a broader addressable market, although international operations also expose the company to regulatory, currency and market-specific risks.

Molbio Diagnostics IPO GMP

The Grey Market Premium (GMP) is an unofficial indicator of market sentiment toward an IPO and can change frequently.

Recent reports indicated that Molbio Diagnostics was commanding a strong premium in the grey market ahead of and during the IPO opening. However, GMP is not an official market indicator and should not be treated as a guarantee of the listing price.

Investors should therefore focus primarily on the company’s fundamentals, valuation, growth prospects and risks rather than making an investment decision solely on GMP.

Molbio Diagnostics IPO – Strengths

1. Strong Position in Point-of-Care Diagnostics

Molbio operates in a healthcare segment where rapid and decentralized diagnostics are becoming increasingly important.

2. Proprietary Truenat Platform

The Truenat platform provides Molbio with a differentiated technology platform and allows multiple diagnostic assays to be developed around the same system.

3. International Presence

The company’s products have gained acceptance in international markets, providing opportunities beyond India’s diagnostics market.

4. Healthcare Industry Growth

Increasing healthcare spending, greater disease screening and the growing need for faster diagnosis could support long-term demand.

5. Investment in R&D

The planned investment in an R&D facility and Centre of Excellence demonstrates the company’s focus on technology and product development.

Risks to Consider

While the business has attractive growth opportunities, investors should also consider the risks.

Customer Concentration

Recent reports have highlighted customer concentration as an important risk, with the company’s largest customers accounting for a significant share of revenue.

Regulatory Risks

Diagnostics is a highly regulated industry. Changes in regulatory requirements, product approvals or healthcare policies could affect the business.

Competition

Molbio operates in a competitive diagnostics industry where technological developments and pricing can influence market share.

International Exposure

A significant international presence provides growth opportunities but also creates exposure to currency fluctuations, regulatory requirements and geopolitical conditions.

IPO Valuation

Investors should compare the IPO valuation with listed diagnostics and healthcare companies before deciding whether the issue offers sufficient value.

Molbio Diagnostics IPO Valuation

The IPO price band has been fixed at ₹768 to ₹807 per equity share.

At the upper end of the price band, the company is seeking a valuation of approximately ₹9,100 crore based on available IPO data.

Investors should compare this valuation with the company’s earnings, growth rate, margins and other listed diagnostics companies.

A strong business does not necessarily mean that an IPO is attractive at every valuation. The price paid remains an important factor in determining potential long-term returns.

Molbio Diagnostics IPO Timeline

The IPO opened on August 10, 2026, and closes on August 12, 2026.

The expected timeline is:

• IPO Opens: August 10, 2026
• IPO Closes: August 12, 2026
• Basis of Allotment: August 13, 2026
• Refunds: August 14, 2026
• Demat Credit: August 14, 2026
• Listing: August 17, 2026

The shares are expected to list on both BSE and NSE.

Molbio Diagnostics IPO Review

Molbio Diagnostics is entering the market at an interesting time for the diagnostics industry.

The company’s key strengths include its Truenat molecular diagnostics platform, point-of-care testing model, international presence, R&D capabilities and exposure to the growing demand for decentralized healthcare.

The proposed IPO investment in R&D and manufacturing infrastructure could further strengthen the company’s ability to develop new products and expand capacity.

At the same time, investors should carefully assess customer concentration, regulatory requirements, competition, international exposure and the valuation being offered in the IPO.

Molbio Diagnostics IPO – Should You Apply?

Molbio Diagnostics could appeal to investors who are comfortable with the risks associated with a growth-oriented healthcare technology company and are looking for long-term exposure to the molecular diagnostics sector.

However, investors should not rely only on the IPO’s GMP or expected listing gains. The company’s valuation, profitability, cash flows, competitive position and future growth potential should be evaluated before subscribing.

IPO investors should read the company’s Red Herring Prospectus (RHP) carefully and consider their own risk tolerance before investing.

Disclaimer

This article is for informational and educational purposes only and should not be considered investment advice. IPO details, GMP and market conditions can change. Investors should verify the latest information from the company’s official filings, RHP and stock exchange disclosures before making an investment decision.